{"_id": "650138edfddc0bb1312fb028", "and": [{"cancer type": {"$in": ["glioblastoma", "gliosarcoma"]}}, {"histologically confirmed diagnosis": "World Health Organization Grade IV malignant glioma"}, {"days since surgical resection": {"$gte": 21}}, {"Karnofsky performance status": {"$gte": 70}}, {"adequate organ function": true}, {"resting baseline O2 saturation by pulse oximetry": {"$gte": 92}}, {"able to provide written informed consent/assent": true}, {"life expectancy": {"$gte": 84}}, {"willingness to discontinue medications associated with risk of Torsades de Pointes": true}, {"medications associated with risk of Torsades de Pointes": {"$in": ["quinidine", "procainamide", "disopyramide", "amiodarone", "erythromycin", "clarithromycin", "chlorpromazine", "haloperidol"]}}, {"lesion size": {"$lt": 4}}, {"prior anti-cancer therapy for glioblastoma": false}, {"negative urine or serum pregnancy test for females of childbearing potential": true}, {"urine test result": {"$in": ["positive", "cannot be confirmed as negative"]}}, {"serum pregnancy test required": true}, {"adequate method of contraception for females and males of childbearing potential": true}, {"abstinence is acceptable": true}, {"use of Optune device": true}, {"$not": {"$or": [{"prior treatment of glioblastoma with radiation and temozolomide": true}, {"evidence of leptomeningeal disease": true}, {"prior treatment with Gliadel": true}, {"unable or unwilling to have a contrast enhanced MRI of brain": true}, {"currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment": true}, {"diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment": true}, {"physiologic doses of steroid therapy by the time of first dose of treatment are allowed": true}, {"known history of active Bacillus Tuberculosis": true}, {"hypersensitivity to pembrolizumab or any of its excipients": true}, {"prior anti-cancer monoclonal antibody within 4 weeks prior to study Day 1 or not recovered from adverse events due to agents administered more than 4 weeks earlier": true}, {"potential participants with \u2264 Grade 2 neuropathy may qualify for the study": true}, {"prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent": true}, {"if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy": true}, {"known additional malignancy that is progressing or requires active treatment": true}, {"basal cell carcinoma of the skin that has undergone potentially curative therapy": true}, {"squamous cell carcinoma of the skin that has undergone potentially curative therapy": true}, {"in situ cervical cancer": true}, {"active autoimmune disease that has required systemic treatment in the past 2 years": true}, {"use of disease modifying agents": true}, {"corticosteroids": true}, {"immunosuppressive drugs": true}, {"known history of, or any evidence of active, interstitial lung disease or non-infectious pneumonitis requiring corticosteroid therapy": true}, {"active serious infection requiring systemic therapy": true}, {"major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to day 1 of treatment on study": true}, {"history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate": true}, {"known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial": true}, {"is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial": true}, {"starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment": true}, {"prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent": true}, {"known history of Human Immunodeficiency Virus": true}, {"known active Hepatitis B or Hepatitis C": true}, {"received a live vaccine within 30 days of planned start of study therapy": true}]}}], "nctId": "NCT03426891", "title": "A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma"}